IN BRIEF: Tissue Regenix eyes profit beat; plots German jv disposal

Tissue Regenix Group PLC - Leeds, England-based regenerative medical devices company - Revenue ...

Alliance News 31 January, 2025 | 9:30PM
Email Form Facebook Twitter LinkedIn RSS

Tissue Regenix Group PLC - Leeds, England-based regenerative medical devices company - Revenue increases 8% to USD28.4 million in the year ending December 31 from USD26.3 million a year prior. In addition, expects to report an adjusted earnings before interest, tax, depreciation and amortisation above expectations. Notes this will mark the second full year of profitability for Tissue Regenix and the fourth year of above-market growth.

Further, plans to sell the not-for-profit German joint venture, GBM-V. Explains the market dynamics of this joint venture have historically reduced the growth rate of the company and reduced its profit margins. The company's review of strategic options is continuing.

Current stock price: 58.16 pence

12-month change: down 2.3%

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Tissue Regenix Group PLC 59.00 GBX 1.72 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures